{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T23:23:22Z","timestamp":1785799402301,"version":"3.56.0"},"reference-count":99,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,12,25]],"date-time":"2014-12-25T00:00:00Z","timestamp":1419465600000},"content-version":"vor","delay-in-days":754,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1111\/1469-0691.12003","type":"journal-article","created":{"date-parts":[[2012,8,30]],"date-time":"2012-08-30T18:17:42Z","timestamp":1346350662000},"page":"1176-1184","source":"Crossref","is-referenced-by-count":146,"title":["Antimicrobial treatment concepts for orthopaedic device-related infection"],"prefix":"10.1016","volume":"18","author":[{"given":"P.","family":"Sendi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Zimmerli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/1469-0691.12003_bib1","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1056\/NEJMra040181","article-title":"Prosthetic-joint infections","volume":"351","author":"Zimmerli","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1111\/1469-0691.12003_bib2","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMcp0905029","article-title":"Clinical practice. Infection associated with prosthetic joints","volume":"361","author":"Del Pozo","year":"2009","journal-title":"N Engl J Med"},{"issue":"suppl 3","key":"10.1111\/1469-0691.12003_bib3","first-page":"iii45","article-title":"The diagnosis and management of prosthetic joint infections","volume":"65","author":"Moran","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/1469-0691.12003_bib4","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.2165\/00003495-200666080-00005","article-title":"Antimicrobial agents in orthopaedic surgery: prophylaxis and treatment","volume":"66","author":"Trampuz","year":"2006","journal-title":"Drugs"},{"key":"10.1111\/1469-0691.12003_bib5","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/jac\/dkm476","article-title":"Tissue concentrations: do we ever learn","volume":"61","author":"Mouton","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/1469-0691.12003_bib6","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1001\/jama.279.19.1537","article-title":"Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group","volume":"279","author":"Zimmerli","year":"1998","journal-title":"JAMA"},{"key":"10.1111\/1469-0691.12003_bib7","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/infdis\/162.1.96","article-title":"Correlation between in vivo and in vitro efficacy of antimicrobial agents against foreign body infections","volume":"162","author":"Widmer","year":"1990","journal-title":"J Infect Dis"},{"issue":"suppl 7","key":"10.1111\/1469-0691.12003_bib8","doi-asserted-by":"crossref","first-page":"S487","DOI":"10.1093\/cid\/cir164","article-title":"Characterization of global patterns and the genetics of fusidic acid resistance","volume":"52","author":"Farrell","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1111\/1469-0691.12003_bib9","doi-asserted-by":"crossref","first-page":"5597","DOI":"10.1128\/AAC.00742-11","article-title":"Reduction in fluoroquinolone use following introduction of ertapenem into a hospital formulary is associated with improvement in susceptibility of Pseudomonas aeruginosa to group 2 carbapenems: a 10-year study","volume":"55","author":"Cook","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/1469-0691.12003_bib10","series-title":"Antibiotics in laboratory medicine","first-page":"719","article-title":"Extravas-cular antimicrobial distribution and the respective blood and urine concentrations in humans","author":"Bamberger","year":"2005"},{"key":"10.1111\/1469-0691.12003_bib11","series-title":"Documed","year":"2012"},{"key":"10.1111\/1469-0691.12003_bib12","series-title":"Antbiotika\u2014Moderne Therapiekonzepte","author":"Wichelhaus","year":"2004"},{"key":"10.1111\/1469-0691.12003_bib13","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1128\/AAC.17.2.199","article-title":"Absorption and disposition kinetics of amoxicillin in normal human subjects","volume":"17","author":"Arancibia","year":"1980","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/1469-0691.12003_bib14","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1128\/AAC.01410-06","article-title":"Population pharmacokinetics at two dose levels and pharmacodynamic profiling of flucloxacillin","volume":"51","author":"Landersdorfer","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/1469-0691.12003_bib15","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1128\/AAC.36.7.1437","article-title":"Pharmacokinetics of meropenem and its metabolite in young and elderly healthy men","volume":"36","author":"Ljungberg","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/1469-0691.12003_bib16","series-title":"Allgemeine und spezielle Pharmakologie und Toxikologie","author":"Forth","year":"1996"},{"key":"10.1111\/1469-0691.12003_bib17","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1086\/600877","article-title":"Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists","volume":"49","author":"Rybak","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1111\/1469-0691.12003_bib18","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2165\/00003088-199222010-00005","article-title":"Pharmacokinetic drug interactions with rifampicin","volume":"22","author":"Venkatesan","year":"1992","journal-title":"Clin Pharmacokinet"},{"key":"10.1111\/1469-0691.12003_bib19","doi-asserted-by":"crossref","unstructured":"Achermann Y, Eigenmann K, Ledergerber B et al. Factors associated with rifampin resistance in staphylococcal periprosthetic joint infections (PJI): a matched case-control study. Infection (in press); http:\/\/www.Doi:10.1007\/s15010-012-0325-7.","DOI":"10.1007\/s15010-012-0325-7"},{"key":"10.1111\/1469-0691.12003_bib20","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/j.1469-0691.2007.01691.x","article-title":"Treatment of staphylococcal prosthetic joint infections with debridement, prosthesis retention and oral rifampicin and fusidic acid","volume":"13","author":"Aboltins","year":"2007","journal-title":"Clin Microbiol Infect"},{"key":"10.1111\/1469-0691.12003_bib21","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/j.1469-0691.2006.01463.x","article-title":"Treatment of acute post-surgical infection of joint arthroplasty","volume":"12","author":"Soriano","year":"2006","journal-title":"Clin Microbiol Infect"},{"key":"10.1111\/1469-0691.12003_bib22","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/jac\/39.2.235","article-title":"Oral treatment of Staphylococcus spp. infected orthopaedic implants with fusidic acid or ofloxacin in combination with rifampicin","volume":"39","author":"Drancourt","year":"1997","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/1469-0691.12003_bib23","first-page":"2265","article-title":"Diffusion in bone tissue of antibiotics","volume":"28","author":"Boselli","year":"1999","journal-title":"Presse Med"},{"key":"10.1111\/1469-0691.12003_bib24","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/cid\/cir842","article-title":"Systemic antibiotic therapy for chronic osteomyelitis in adults","volume":"54","author":"Spellberg","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1111\/1469-0691.12003_bib25","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2165\/00003088-200948020-00002","article-title":"Penetration of antibacterials into bone: pharmacokinetic, pharmacodynamic and bioanalytical considerations","volume":"48","author":"Landersdorfer","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"10.1111\/1469-0691.12003_bib26","doi-asserted-by":"crossref","first-page":"5161","DOI":"10.1128\/AAC.00027-10","article-title":"Safety and efficacy of moxifloxacin monotherapy for treatment of orthopedic implant-related staphylococcal infections","volume":"54","author":"San","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/1469-0691.12003_bib27","doi-asserted-by":"crossref","first-page":"945","DOI":"10.3109\/00365528509088853","article-title":"Comparative pharmacokinetics of metronidazole and tinidazole and their tissue penetration","volume":"20","author":"Bergan","year":"1985","journal-title":"Scand J Gastroenterol"},{"key":"10.1111\/1469-0691.12003_bib28","doi-asserted-by":"crossref","first-page":"4308","DOI":"10.1128\/AAC.00352-11","article-title":"Linezolid plus rifampin as a salvage therapy in prosthetic joint infections treated without removing the implant","volume":"55","author":"Gomez","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/1469-0691.12003_bib29","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s15010-004-4020-1","article-title":"Management of infection associated with total hip arthroplasty according to a treatment algorithm","volume":"32","author":"Giulieri","year":"2004","journal-title":"Infection"},{"key":"10.1111\/1469-0691.12003_bib30","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1469-0691.2006.01378.x","article-title":"Outcome of prosthetic knee-associated infection: evaluation of 40 consecutive episodes at a single centre","volume":"12","author":"Laffer","year":"2006","journal-title":"Clin Microbiol Infect"},{"key":"10.1111\/1469-0691.12003_bib31","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1469-0691.2010.03244.x","article-title":"Outcome and predictors of treatment failure in early post-surgical prosthetic joint infections due to Staphylococcus aureus treated with debridement","volume":"17","author":"Vilchez","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"10.1111\/1469-0691.12003_bib32","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s10096-007-0289-1","article-title":"Efficacy and tolerability of prolonged linezolid therapy in the treatment of orthopedic implant infections","volume":"26","author":"Soriano","year":"2007","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1111\/1469-0691.12003_bib33","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1093\/clinids\/14.6.1251","article-title":"Antimicrobial treatment of orthopedic implant-related infections with rifampin combinations","volume":"14","author":"Widmer","year":"1992","journal-title":"Clin Infect Dis"},{"key":"10.1111\/1469-0691.12003_bib34","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/cid\/cir402","article-title":"Outcome and predictors of treatment failure in total hip\/knee prosthetic joint infections due to Staphylococcus aureus","volume":"53","author":"Senneville","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1111\/1469-0691.12003_bib35","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0732-8893(97)00140-5","article-title":"Antimicrobial susceptibility of viridans group streptococci","volume":"29","author":"Tuohy","year":"1997","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"suppl C","key":"10.1111\/1469-0691.12003_bib36","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/eurheartj\/5.suppl_C.33","article-title":"Antibiotic susceptibility of streptococcal strains associated with infective endocarditis","volume":"5","author":"Etienne","year":"1984","journal-title":"Eur Heart J"},{"key":"10.1111\/1469-0691.12003_bib37","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000239546","article-title":"Antibiotic susceptibility of alpha- and nonhemolytic streptococci from patients and healthy adults to 24 antimicrobial drugs","volume":"43","author":"Traub","year":"1997","journal-title":"Chemotherapy"},{"key":"10.1111\/1469-0691.12003_bib38","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/oxfordjournals.jac.a020858","article-title":"Antimicrobial susceptibility of 278 streptococcal blood isolates to seven antimicrobial agents","volume":"39","author":"Renneberg","year":"1997","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/1469-0691.12003_bib39","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0732-8893(98)00155-2","article-title":"Incidence of erythromycin resistance in Streptococcus pyogenes: a 10-year study","volume":"33","author":"Betriu","year":"1999","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1111\/1469-0691.12003_bib40","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0732-8893(00)00194-2","article-title":"Antimicrobial susceptibility of Abiotrophia adiacens and Abiotrophia defectiva","volume":"38","author":"Tuohy","year":"2000","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1111\/1469-0691.12003_bib41","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1128\/JCM.41.9.4043-4048.2003","article-title":"Biofilm formation by group A streptococci: is there a relationship with treatment failure","volume":"41","author":"Conley","year":"2003","journal-title":"J Clin Microbiol"},{"issue":"suppl 3","key":"10.1111\/1469-0691.12003_bib42","doi-asserted-by":"crossref","first-page":"S586","DOI":"10.1093\/clinids\/5.Supplement_3.S586","article-title":"In vitro activity of penicillin and rifampin against group B streptococci","volume":"5","author":"Maduri-Traczewski","year":"1983","journal-title":"Rev Infect Dis"},{"key":"10.1111\/1469-0691.12003_bib43","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1016\/j.jinf.2004.10.017","article-title":"Prosthetic valve endocarditis from Granulicatella adiacens (nutritionally variant streptococci)","volume":"51","author":"Jeng","year":"2005","journal-title":"J Infect"},{"key":"10.1111\/1469-0691.12003_bib44","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s15010-002-2104-3","article-title":"Vertebral osteomyelitis and endocarditis of a pacemaker lead due to Granulicatella (Abiotrophia) adiacens","volume":"30","author":"Rosenthal","year":"2002","journal-title":"Infection"},{"key":"10.1111\/1469-0691.12003_bib45","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jhin.2011.04.022","article-title":"Group B Streptococcus in prosthetic hip and knee joint-associated infections","volume":"79","author":"Sendi","year":"2012","journal-title":"J Hosp Infect"},{"issue":"suppl 3","key":"10.1111\/1469-0691.12003_bib46","doi-asserted-by":"crossref","first-page":"S528","DOI":"10.1093\/clinids\/5.Supplement_3.S528","article-title":"Therapeutic potential of rifampin in enterococcal infections","volume":"5","author":"Moellering","year":"1983","journal-title":"Rev Infect Dis"},{"key":"10.1111\/1469-0691.12003_bib47","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1128\/AAC.20.4.491","article-title":"Rifampin, ampicillin, streptomycin, and their combinations in the treatment of enterococcal pyelonephritis in rats","volume":"20","author":"Oill","year":"1981","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/1469-0691.12003_bib48","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1128\/AAC.9.3.448","article-title":"Effects of ampicillin-amikacin and ampicillin-rifampin on enterococci","volume":"9","author":"Iannini","year":"1976","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/1469-0691.12003_bib49","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/0002-9343(80)90118-7","article-title":"Enterococcal meningitis: combined vancomycin and rifampin therapy","volume":"68","author":"Ryan","year":"1980","journal-title":"Am J Med"},{"key":"10.1111\/1469-0691.12003_bib50","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/jac\/dkr477","article-title":"Effectiveness of ciprofloxacin or linezolid in combination with rifampicin against Enterococcus faecalis in biofilms","volume":"67","author":"Holmberg","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/1469-0691.12003_bib51","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1007\/s10096-011-1498-1","article-title":"In vitro activity and in vivo efficacy of tigecycline alone and in combination with daptomycin and rifampin against Gram-positive cocci isolated from surgical wound infection","volume":"31","author":"Silvestri","year":"2011","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1111\/1469-0691.12003_bib52","doi-asserted-by":"crossref","DOI":"10.1007\/s11999-012-2374-8","article-title":"Low rate of infection control in enterococcal periprosthetic joint infections","author":"Rasouli","year":"2012","journal-title":"Clin Orthop Relat Res"},{"key":"10.1111\/1469-0691.12003_bib53","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/j.1600-0463.2012.02905.x","article-title":"Antibiotic susceptibility in prostate-derived Propionibacterium acnes isolates","volume":"120","author":"Olsson","year":"2012","journal-title":"APMIS"},{"key":"10.1111\/1469-0691.12003_bib54","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s00402-007-0454-0","article-title":"Propionibacterium spp. in prosthetic joint infections: a diagnostic challenge","volume":"128","author":"Zappe","year":"2008","journal-title":"Arch Orthop Trauma Surg"},{"key":"10.1111\/1469-0691.12003_bib55","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1128\/AAC.05552-11","article-title":"Role of rifampin against Propionibacterium acnes biofilm in vitro and in an experimental foreign-body infection model","volume":"56","author":"Furustrand","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/1469-0691.12003_bib56","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.clineuro.2009.04.003","article-title":"Propionibacterium skull osteomyelitis treated with daptomycin","volume":"111","author":"Ghosh","year":"2009","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1111\/1469-0691.12003_bib57","first-page":"477","article-title":"Severe infections caused by Propionibacterium acnes: an underestimated pathogen in late postoperative infections","volume":"69","author":"Jakab","year":"1996","journal-title":"Yale J Biol Med"},{"key":"10.1111\/1469-0691.12003_bib58","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1086\/588477","article-title":"Propionibacterium acnes postoperative shoulder arthritis: an emerging clinical entity","volume":"46","author":"Levy","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1111\/1469-0691.12003_bib59","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s10096-005-0040-8","article-title":"Arthroplastic and osteosynthetic infections due to Propionibacterium acnes: a retrospective study of 52 cases, 1995\u20132002","volume":"24","author":"Lutz","year":"2005","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1111\/1469-0691.12003_bib60","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.anaerobe.2009.10.009","article-title":"Propionibacterium acnes as an etiological agent of arthroplastic and osteosynthetic infections\u2014two cases with specific clinical presentation including formation of draining fistulae","volume":"16","author":"Soderquist","year":"2012","journal-title":"Anaerobe"},{"key":"10.1111\/1469-0691.12003_bib61","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jinf.2007.02.006","article-title":"Propionibacterium acnes: an agent of prosthetic joint infection and colonization","volume":"55","author":"Zeller","year":"2007","journal-title":"J Infect"},{"key":"10.1111\/1469-0691.12003_bib62","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/j.1469-0691.2010.03361.x","article-title":"Gram-negative prosthetic joint infection treated with debridement, prosthesis retention and antibiotic regimens including a fluoroquinolone","volume":"17","author":"Aboltins","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"10.1111\/1469-0691.12003_bib63","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.arth.2011.03.044","article-title":"Prosthetic joint infection caused by gram-negative organisms","volume":"26","author":"Zmistowski","year":"2011","journal-title":"J Arthroplasty"},{"key":"10.1111\/1469-0691.12003_bib64","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1086\/605593","article-title":"Gram-negative prosthetic joint infections: risk factors and outcome of treatment","volume":"49","author":"Hsieh","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1111\/1469-0691.12003_bib65","doi-asserted-by":"crossref","first-page":"4772","DOI":"10.1128\/AAC.00188-09","article-title":"Outcome of acute prosthetic joint infections due to gram-negative bacilli treated with open debridement and retention of the prosthesis","volume":"53","author":"Martinez-Pastor","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/1469-0691.12003_bib66","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3109\/07853890109002073","article-title":"Multidrug-resistant bacteria: overcoming antibiotic permeability barriers of gram-negative bacteria","volume":"33","author":"Savage","year":"2001","journal-title":"Ann Med"},{"key":"10.1111\/1469-0691.12003_bib67","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1128\/MMBR.56.3.395-411.1992","article-title":"Agents that increase the permeability of the outer membrane","volume":"56","author":"Vaara","year":"1992","journal-title":"Microbiol Rev"},{"issue":"suppl 3","key":"10.1111\/1469-0691.12003_bib68","doi-asserted-by":"crossref","first-page":"S407","DOI":"10.1093\/clinids\/5.Supplement_3.S407","article-title":"Rifampin: mechanisms of action and resistance","volume":"5","author":"Wehrli","year":"1983","journal-title":"Rev Infect Dis"},{"key":"10.1111\/1469-0691.12003_bib69","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ijantimicag.2009.08.011","article-title":"Rifampicin combined regimens for gram-negative infections: data from the literature","volume":"35","author":"Drapeau","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"10.1111\/1469-0691.12003_bib70","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1128\/CMR.00034-09","article-title":"Rifampin combination therapy for nonmycobacterial infections","volume":"23","author":"Forrest","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"10.1111\/1469-0691.12003_bib71","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1007\/s10096-009-0774-9","article-title":"Combination antibiotic susceptibility of biofilm-grown Burkholderia cepacia and Pseudomonas aeruginosa isolated from patients with pulmonary exacerbations of cystic fibrosis","volume":"28","author":"Dales","year":"2009","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1111\/1469-0691.12003_bib72","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1128\/AAC.27.4.615","article-title":"In vitro activities of rifapentine and rifampin, alone and in combination with six other antibiotics, against methicillin-susceptible and methicillin-resistant staphylococci of different species","volume":"27","author":"Varaldo","year":"1985","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/1469-0691.12003_bib73","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1159\/000168004","article-title":"The activity of rifampin and analogs against Staphylococcus epidermidis biofilms in a CAPD environment model","volume":"9","author":"Obst","year":"1989","journal-title":"Am J Nephrol"},{"key":"10.1111\/1469-0691.12003_bib74","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1179\/joc.2001.13.2.167","article-title":"Effects of continuous or pulsed exposure to rifabutin and sparfloxacin on the intracellular growth of Staphylococcus aureus and Mycobacterium tuberculosis","volume":"13","author":"Fietta","year":"2001","journal-title":"J Chemother"},{"key":"10.1111\/1469-0691.12003_bib75","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1093\/jac\/dkn133","article-title":"In vitro pharmacodynamics of novel rifamycin ABI-0043 against Staphylococcus aureus","volume":"62","author":"Tsuji","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/1469-0691.12003_bib76","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1128\/AAC.00120-07","article-title":"Efficacy of a novel rifamycin derivative, ABI-0043, against Staphylococcus aureus in an experimental model of foreign-body infection","volume":"51","author":"Trampuz","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/1469-0691.12003_bib77","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1086\/650540","article-title":"Gram-negative versus gram-positive prosthetic joint infections","volume":"50","author":"Uckay","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1111\/1469-0691.12003_bib78","doi-asserted-by":"crossref","first-page":"611","DOI":"10.3109\/00365549009027105","article-title":"Salmonella infection in total hip replacement: tests to predict the outcome of antimicrobial therapy","volume":"22","author":"Widmer","year":"1990","journal-title":"Scand J Infect Dis"},{"key":"10.1111\/1469-0691.12003_bib79","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/cid\/cir935","article-title":"The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis","volume":"54","author":"van Hal","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1111\/1469-0691.12003_bib80","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1021\/cb300007j","article-title":"Redesign of glycopeptide antibiotics: back to the future","volume":"7","author":"James","year":"2012","journal-title":"ACS Chem Biol"},{"key":"10.1111\/1469-0691.12003_bib81","doi-asserted-by":"crossref","first-page":"525","DOI":"10.2165\/00003495-200161040-00008","article-title":"Linezolid: a review of its use in the management of serious gram-positive infections","volume":"61","author":"Perry","year":"2001","journal-title":"Drugs"},{"key":"10.1111\/1469-0691.12003_bib82","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/jac\/dkf066","article-title":"Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement","volume":"50","author":"Lovering","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/1469-0691.12003_bib83","doi-asserted-by":"crossref","first-page":"3438","DOI":"10.1128\/AAC.44.12.3438-3440.2000","article-title":"Linezolid therapy of Staphylococcus aureus experimental osteomyelitis","volume":"44","author":"Patel","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/1469-0691.12003_bib84","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s10096-010-0902-6","article-title":"In vitro antimicrobial synergy testing of coagulase-negative staphylococci isolated from prosthetic joint infections using Etest and with a focus on rifampicin and linezolid","volume":"29","author":"Hellmark","year":"2010","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1111\/1469-0691.12003_bib85","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1128\/AAC.00775-08","article-title":"Linezolid alone or combined with rifampin against methicillin-resistant Staphylococcus aureus in experimental foreign-body infection","volume":"53","author":"Baldoni","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/1469-0691.12003_bib86","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.clinthera.2006.08.001","article-title":"Effectiveness and tolerability of prolonged linezolid treatment for chronic osteomyelitis: a retrospective study","volume":"28","author":"Senneville","year":"2006","journal-title":"Clin Ther"},{"key":"10.1111\/1469-0691.12003_bib87","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.diagmicrobio.2007.04.006","article-title":"Efficacy and safety of linezolid for Gram-positive orthopedic infections: a prospective case series","volume":"59","author":"Rao","year":"2007","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1111\/1469-0691.12003_bib88","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1093\/jac\/dkq281","article-title":"Tolerability of prolonged linezolid therapy in bone and joint infection: protective effect of rifampicin on the occurrence of anaemia","volume":"65","author":"Legout","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/1469-0691.12003_bib89","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0025-6196(11)62596-2","article-title":"Linezolid therapy for orthopedic infections","volume":"79","author":"Razonable","year":"2004","journal-title":"Mayo Clin Proc"},{"key":"10.1111\/1469-0691.12003_bib90","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.2165\/00003495-200767100-00008","article-title":"Daptomycin: a review of its use in the management of complicated skin and soft-tissue infections and Staphylococcus aureus bacteraemia","volume":"67","author":"Hair","year":"2007","journal-title":"Drugs"},{"key":"10.1111\/1469-0691.12003_bib91","doi-asserted-by":"crossref","first-page":"4665","DOI":"10.1128\/AAC.48.12.4665-4672.2004","article-title":"Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model","volume":"48","author":"LaPlante","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/1469-0691.12003_bib92","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1128\/AAC.00047-09","article-title":"Efficacy of daptomycin in implant-associated infection due to methicillin-resistant Staphylococcus aureus: importance of combination with rifampin","volume":"53","author":"John","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/1469-0691.12003_bib93","doi-asserted-by":"crossref","first-page":"4255","DOI":"10.1128\/AAC.00824-07","article-title":"Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells","volume":"51","author":"Mascio","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"suppl 1","key":"10.1111\/1469-0691.12003_bib94","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1086\/647938","article-title":"Daptomycin: from the mountain to the clinic, with essential help from Francis Tally, MD","volume":"50","author":"Eisenstein","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1111\/1469-0691.12003_bib95","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1086\/600039","article-title":"Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program","volume":"49","author":"Figueroa","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1111\/1469-0691.12003_bib96","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.1128\/AAC.00675-11","article-title":"Adjunctive rifampin is crucial to optimizing daptomycin efficacy against rabbit prosthetic joint infection due to methicillin-resistant Staphylococcus aureus","volume":"55","author":"Saleh-Mghir","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/1469-0691.12003_bib97","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/01.blo.0000224021.73163.61","article-title":"Uncertain efficacy of daptomycin for prosthetic joint infections: a prospective case series","volume":"451","author":"Rao","year":"2006","journal-title":"Clin Orthop Relat Res"},{"key":"10.1111\/1469-0691.12003_bib98","doi-asserted-by":"crossref","first-page":"5251","DOI":"10.1128\/AAC.00226-10","article-title":"Efficacy of usual and high doses of daptomycin in combination with rifampin versus alternative therapies in experimental foreign-body infection by methicillin-resistant Staphylococcus aureus","volume":"54","author":"Garrigos","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/1469-0691.12003_bib99","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/j.amjmed.2007.07.010","article-title":"Clinical experience with daptomycin for the treatment of patients with osteomyelitis","volume":"120","author":"Lamp","year":"2007","journal-title":"Am J Med"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X1460803X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X1460803X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T01:44:33Z","timestamp":1594604673000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X1460803X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":99,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["S1198743X1460803X"],"URL":"https:\/\/doi.org\/10.1111\/1469-0691.12003","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12]]}}}